Tempest Therapeutics
TPST
22 hedge funds and large institutions have $1.29M invested in Tempest Therapeutics in 2026 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
5% more funds holding
Funds holding: 21 → 22 (+1)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.01% less ownership
Funds ownership: 15.98% → 15.97% (-0.01%)
43% less capital invested
Capital invested by funds: $2.26M → $1.29M (-$970K)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$103K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.54K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$46 |
| 4 |
Citigroup
New York
|
+$19 |
| 5 |
JP Morgan Chase
New York
|
+$12 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$388K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$31.4K |
| 3 |
DS
DRW Securities
Chicago,
Illinois
|
-$30K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$203 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$107 |
TPST Hedge Fund Activity: Q1 2026 in Review
22 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q1 2026, worth a combined $1.29M — down 43% from $2.26M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TPST positions and 2 closed out — a net gain of 3 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $103K. The largest seller was Sabby Management, cutting an estimated $388K.
- 22 institutional investors held Tempest Therapeutics (TPST) as of Q1 2026, up from 21 in Q4 2025.
- Funds reported $1.29M of Tempest Therapeutics stock for Q1 2026, down 43% quarter-over-quarter.
- 5 funds opened new Tempest Therapeutics positions in Q1 2026 and 2 closed out, a net change of +3 holders.
- The largest Tempest Therapeutics buyer in Q1 2026 was Geode Capital Management, an estimated $103K added.
- The largest Tempest Therapeutics seller in Q1 2026 was Sabby Management, an estimated $388K sold.
Based on aggregated 13F filings for Q1 2026.